<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594736</url>
  </required_header>
  <id_info>
    <org_study_id>MJ-MRI-ORSIRO_OCT-V3.1</org_study_id>
    <nct_id>NCT01594736</nct_id>
  </id_info>
  <brief_title>ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography</brief_title>
  <acronym>ORSIRO_OCT</acronym>
  <official_title>Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized trial will compare the extent of covered stent strut segments by
      assessed by Optical Coherence Tomography (OCT) of the ORSIRO DES with that of the XIENCE
      PRIME DES, which is the standard of choice of contemporary drug eluting stents (DES).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ORSIRO drug eluting stent exhibits a favourable vascular healing profile from baseline to
      6 months assessed by optical coherence tomography (OCT). Patients with symptomatic coronary
      artery disease without cardiogenic shock who will undergo coronary angiography and willing to
      participate in the trial will receive before the procedure a loading dose of P2Y12
      antagonists (clopidogrel, prasugrel or ticagrelor). Eligible patients who do not meet the
      exclusion criteria and for whom PCI will be considered as the appropriate form of
      revascularization will be randomly assigned to the ORSIRO or the XIENCE PRIME DES in the
      relation 1 x ORSIRO: 1 x XIENCE PRIME. All patients will receive periprocedural intravenous
      aspirin and heparin or bivalirudin. After the intervention patients will receive aspirin
      indefinitely and P2Y12 antagonists for at least 6 months. The intravascular imaging by OCT
      will be performed at the 6-8 months follow-up angiography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of stent strut coverage at 6 months follow-up assessed by OCT for each visible strut segment</measure>
    <time_frame>6-18 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>ORSIRO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE PRIME DES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORSIRO</intervention_name>
    <description>due randomization ORSIRO will be implanted</description>
    <arm_group_label>ORSIRO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME DES</intervention_name>
    <description>due randomization XIENCE PRIME DES will be implanted</description>
    <arm_group_label>XIENCE PRIME DES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of ≥ 50% stenosis located in native coronary vessels.

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study.

          -  In women with childbearing potential a negative pregnancy test is mandatory.

          -  AHA type A, B1 and B2 lesions.

        Exclusion Criteria:

          -  Lesion length &gt; 25 mm requiring a stent length &gt; 28 mm

          -  Target lesion located in the left main trunk.

          -  In-stent restenosis.

          -  Acute myocardial infarction

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 18 months or that may result in
             protocol non-compliance.

          -  Known allergy to the study medications: sirolimus, everolimus

          -  Inability to take dual antiplatelet therapy for at least 6 months.

          -  The presence of bifurcation lesions

          -  The presence of calcified lesions

          -  Pregnancy (present, suspected or planned) or positive pregnancy test.

          -  Previous enrollment in this trial.

          -  Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Joner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

